Skip to main content

bevacizumab

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, bevacizumab 7.5 mg/kg dose in combination with carboplatin and paclitaxel can continue to be made available within NHS Wales for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer at high risk for progression. High risk is defined as: International Federation of Gynaecology and Obstetrics [FIGO] stage III debulked but residual disease more than 1.0 cm or stage IV disease, or stage III disease at presentation and requiring neoadjuvant chemotherapy due to low likelihood of optimal primary surgical cytoreduction.

Bevacizumab 7.5 mg/kg is not licensed to treat this indication and is therefore off-label. Each provider organisation must ensure all internal governance arrangements are completed before these medicines are prescribed in combination.

The risks and benefits of the off-label use of bevacizumab for this indication should be clearly stated and discussed with the patient to allow informed consent.

In June 2019 OWMAG recommended this treatment in NHS Wales, in February 2024 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

Next review: this advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision (with start and stop criteria and evidence review): Low dose bevacizumab for ovarian cancer (OW01 2023 review) (PDF, 91Kb)

Medicine details

Medicine name bevacizumab
Formulation concentrate for solution for infusion
Reference number OW01
Indication

At a dose of 7.5 mg/kg in combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer at high risk of progression

Company Various
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status One Wales interim decision
Date of issue June 2019
Date of last review February 2024
Follow AWTTC: